APA

Meraviglia S., Eberl M., Vermijlen D., Todaro M., Buccheri S., Cicero G., La Mendola C., Guggino G., D'Asaro M., Orlando V., Scarpa F., Roberts A., Caccamo N., Stassi G., Dieli F. & Hayday A. C. (20100827). In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. : Clinical and experimental immunology.

Chicago

Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N, Stassi G, Dieli F and Hayday A C. 20100827. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. : Clinical and experimental immunology.

Harvard

Meraviglia S., Eberl M., Vermijlen D., Todaro M., Buccheri S., Cicero G., La Mendola C., Guggino G., D'Asaro M., Orlando V., Scarpa F., Roberts A., Caccamo N., Stassi G., Dieli F. and Hayday A. C. (20100827). In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. : Clinical and experimental immunology.

MLA

Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N, Stassi G, Dieli F and Hayday A C. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. : Clinical and experimental immunology. 20100827.